Heterodimerization of type A and B cholecystokinin receptors enhance signaling and promote cell growth.
about
Distinct molecular mechanisms for agonist peptide binding to types A and B cholecystokinin receptors demonstrated using fluorescence spectroscopyEffects of cholecystokinin-58 on type 1 cholecystokinin receptor function and regulationKrüppel-like factor 11 regulates the expression of metabolic genes via an evolutionarily conserved protein interaction domain functionally disrupted in maturity onset diabetes of the young.Ligand-dependent differences in the internalization of endothelin A and endothelin B receptor heterodimers.Up-regulation of cholesterol absorption is a mechanism for cholecystokinin-induced hypercholesterolemiaCCK(2) receptor splice variant with intron 4 retention in human gastrointestinal and lung tumours.A type 1 cholecystokinin receptor mutant that mimics the dysfunction observed for wild type receptor in a high cholesterol environment.Cholecystokinin receptor antagonist halts progression of pancreatic cancer precursor lesions and fibrosis in miceMonitoring the formation of dynamic G-protein-coupled receptor-protein complexes in living cells.The G protein-coupled receptor rhodopsin in the native membraneDevelopment of a highly selective allosteric antagonist radioligand for the type 1 cholecystokinin receptor and elucidation of its molecular basis of bindingExpression of cholecystokinin-2/gastrin receptor in the murine pancreas modulates cell adhesion and cell differentiation in vivo.Differential sensitivity of types 1 and 2 cholecystokinin receptors to membrane cholesterol.Ligand-induced internalization of the type 1 cholecystokinin receptor independent of recognized signaling activityMolecular basis for binding and subtype selectivity of 1,4-benzodiazepine antagonist ligands of the cholecystokinin receptor.Functional compensation between cholecystokinin-1 and -2 receptors in murine paraventricular nucleus neurons.Monitoring the state of cholecystokinin receptor oligomerization after ligand binding using decay of time-resolved fluorescence anisotropyMembrane cholesterol affects stimulus-activity coupling in type 1, but not type 2, CCK receptors: use of cell lines with elevated cholesterol.Plasma glutamate-modulated interaction of A2AR and mGluR5 on BMDCs aggravates traumatic brain injury-induced acute lung injurySecretin receptor oligomers form intracellularly during maturation through receptor core domains.Transmembrane segment peptides can disrupt cholecystokinin receptor oligomerization without affecting receptor function.Direct demonstration of unique mode of natural peptide binding to the type 2 cholecystokinin receptor using photoaffinity labeling.Synthesis and in vitro characterization of radioiodinatable benzodiazepines selective for type 1 and type 2 cholecystokinin receptors.Pattern of intra-family hetero-oligomerization involving the G-protein-coupled secretin receptor.Thermodynamic analysis of ligands at cholecystokinin CCK2 receptors in rat cerebral cortex.Induced association of mu opioid (MOP) and type 2 cholecystokinin (CCK2) receptors by novel bivalent ligands.Fluorescent indicators distributed throughout the pharmacophore of cholecystokinin provide insights into distinct modes of binding and activation of type A and B cholecystokinin receptors.
P2860
Q28291059-71FE6333-044D-47D8-A5BE-9F9E334844CBQ28576205-B8332BA7-0073-463F-8645-D93A3CF34DBFQ30009871-E4A720F2-6BA2-4D8F-BC71-8CB179426A49Q30830250-2C7A5372-4BCD-4353-BD2C-5C0260662729Q33676535-3CE14633-4C0E-4C16-B85A-20B9B6844A2FQ33925682-EAEAF629-FD79-4B09-9DB7-57F3F7BC6196Q34073933-20D7D890-E372-4B20-AE01-1F32472CA49FQ34167464-9C3373ED-0814-4523-B60C-B64E3F70F325Q34361815-7040A1F6-CDAE-4D86-89E6-766EDF6D349BQ34432609-4D82A84E-CA15-4FB4-B663-B84B1CB7381DQ34785475-03C6EF3A-E74E-4342-8BE9-E51491B0B7E9Q35103556-80F90825-C5F1-4C0B-BB56-D4F6D3959E31Q35625928-88BBF2DF-5770-4DA0-8E64-71797E46ED9EQ35779987-612FDC6E-9B8C-457B-A112-D212F69B5D3BQ36002904-1C3A13FB-9CCB-48A3-9585-3D3592651DE4Q36407929-2A0606A6-7D88-4D31-B2F5-A1B6EB8DE3D8Q36634597-4D59CB01-2C0D-44C3-B2ED-C4EAC64A332AQ36654207-7C5EE4FD-0C22-45D1-B90B-E004D737686DQ36750067-B3671EB0-373B-4929-93B3-94C9B25790EEQ36826025-500E47CA-E16E-4944-BB09-7C922F166FC8Q36978929-2F4A5E97-577F-4123-8125-536D68A846F4Q37084882-92BB7444-B935-4BFC-9BBE-39083B32C2F1Q37152806-B3A05BD9-BD00-4E57-AEAA-47C99047667DQ37430299-4D3E0612-FDDE-4F80-BBD9-2742D53CB98CQ38505357-1F88E652-E8F8-4652-80D5-97EA93D2F8B8Q43169496-5D05CBA3-5BB1-4821-93A2-7A19A6447EC4Q50727408-DF3CBA37-E975-4EDB-9BBB-4DA450264182
P2860
Heterodimerization of type A and B cholecystokinin receptors enhance signaling and promote cell growth.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Heterodimerization of type A a ...... aling and promote cell growth.
@en
Heterodimerization of type A a ...... aling and promote cell growth.
@nl
type
label
Heterodimerization of type A a ...... aling and promote cell growth.
@en
Heterodimerization of type A a ...... aling and promote cell growth.
@nl
prefLabel
Heterodimerization of type A a ...... aling and promote cell growth.
@en
Heterodimerization of type A a ...... aling and promote cell growth.
@nl
P2093
P2860
P356
P1476
Heterodimerization of type A a ...... aling and promote cell growth.
@en
P2093
Eileen L Holicky
Kaleeckal G Harikumar
Laurence J Miller
Zhi-Jie Cheng
P2860
P304
52972-52979
P356
10.1074/JBC.M310090200
P407
P577
2003-10-08T00:00:00Z